BioSpace News Archive

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with high unmet medical need, is pleased to announce the appointment of Dr. Manuel López-Figueroa of Bay City Capital as an independent director.

IsoPlexis, the leader in functional cellular proteomics, today announced the appointment of John Strahley as Chief Financial Officer.

Alcon, the global leader in eye care dedicated to helping people see brilliantly, will present data that further supports advancements in cataract surgery during the virtual American Society of Cataract and Refractive Surgery (ASCRS) 2020 annual meeting, taking place May 16-17.

Singlera Genomics completed their second Pre-Submission Meeting with the US FDA Center for Devices and Radiological Health, Office of In Vitro Diagnostics on April 21, 2020, after an initial Pre-Submission Meeting in the fall of 2019.

BGI Genomics announced that its Real-time fluorescent RT-PCR kit for detecting 2019-nCoV has been listed as eligible for World Health Organization (WHO) procurement under the WHO Emergency Use Listing (EUL) process.

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, a Medicare Administrative Contractor (MAC), has issued positive coverage for the Prospera donor-derived cell-free DNA (dd-cfDNA) test.

Augmedix now offers two tiers of best-in-class medical documentation services so clinicians can focus less on administrative tasks and more on what matters most: patient care.

ACR Releases Gout Management Guideline with Emphasis on Treat-to-Target Strategy for Urate Lowering Therapy

Akouos, a precision genetic medicine company developing gene therapies to potentially restore, improve and preserve hearing, announced that data from its inner ear gene therapy platform will be presented during the 23rd American Society of Gene and Cell Therapy Annual Meeting, which will be held virtually May 12-15, 2020.

Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases, provided a clinical program update and reported financial results for the first quarter ended March 31, 2020.